Mutual of America Capital Management LLC Has $8.59 Million Stake in Zoetis Inc. (NYSE:ZTS)

Mutual of America Capital Management LLC cut its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 3.7% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 52,189 shares of the company's stock after selling 1,978 shares during the period. Mutual of America Capital Management LLC's holdings in Zoetis were worth $8,593,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of ZTS. Vanguard Group Inc. grew its stake in shares of Zoetis by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 41,366,877 shares of the company's stock valued at $6,739,905,000 after purchasing an additional 120,158 shares during the period. Geode Capital Management LLC grew its holdings in shares of Zoetis by 1.8% in the 4th quarter. Geode Capital Management LLC now owns 10,617,897 shares of the company's stock worth $1,726,075,000 after purchasing an additional 190,137 shares during the last quarter. Polen Capital Management LLC grew its stake in Zoetis by 17.5% during the fourth quarter. Polen Capital Management LLC now owns 7,483,194 shares of the company's stock worth $1,219,237,000 after buying an additional 1,116,541 shares during the last quarter. Wellington Management Group LLP raised its position in Zoetis by 78.5% in the 4th quarter. Wellington Management Group LLP now owns 6,958,543 shares of the company's stock valued at $1,133,755,000 after purchasing an additional 3,059,255 shares during the last quarter. Finally, Northern Trust Corp lifted its position in Zoetis by 13.3% during the 4th quarter. Northern Trust Corp now owns 6,426,394 shares of the company's stock worth $1,047,052,000 after buying an additional 755,893 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Stock Performance

Shares of ZTS traded up $0.72 during mid-day trading on Monday, hitting $155.68. 1,986,473 shares of the company's stock were exchanged, compared to its average volume of 3,011,381. The company has a quick ratio of 1.04, a current ratio of 1.74 and a debt-to-equity ratio of 1.12. Zoetis Inc. has a 52 week low of $139.70 and a 52 week high of $200.33. The stock's 50-day simple moving average is $161.32 and its 200-day simple moving average is $161.82. The firm has a market cap of $69.31 billion, a price-to-earnings ratio of 27.95, a price-to-earnings-growth ratio of 2.57 and a beta of 0.91.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.40 by $0.08. The firm had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.20 billion. Zoetis had a net margin of 27.12% and a return on equity of 55.48%. The business's revenue for the quarter was up 1.4% on a year-over-year basis. During the same period in the prior year, the company posted $1.38 earnings per share. On average, equities research analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Friday, July 18th will be given a $0.50 dividend. The ex-dividend date of this dividend is Friday, July 18th. This represents a $2.00 dividend on an annualized basis and a yield of 1.28%. Zoetis's dividend payout ratio is currently 35.91%.

Insider Buying and Selling at Zoetis

In other news, EVP Roxanne Lagano sold 652 shares of Zoetis stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total transaction of $110,840.00. Following the sale, the executive vice president directly owned 15,129 shares of the company's stock, valued at approximately $2,571,930. This trade represents a 4.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 0.16% of the company's stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on ZTS shares. UBS Group decreased their price target on Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a report on Wednesday, May 7th. Stifel Nicolaus lowered Zoetis from a "buy" rating to a "hold" rating and dropped their price target for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Finally, Piper Sandler increased their target price on Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a report on Monday, May 12th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $212.13.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.